Higher Human T Lymphotropic Virus (HTLV) provirus load is associated with HTLV-I versus HTLV-II, with HTLV-II subtype A versus B, and with male sex and a history of blood transfusion

Journal of Infectious Diseases

Volumn 190, Issue 3, 2004, Pages 504-510

  Murphy, Edward L ^a,b   Lee, Tzong Hae ^b   Chafets, Daniel ^b   Nass, Catharie C ^c   Wang, Baoguang ^d   Loughlin, Katharine ^d   Smith, Donna ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b BLOOD SYSTEMS RESEARCH INSTITUTE   (United States)

^c AMERICAN RED CROSS BLOOD SERVICES   (United States)

^d WESTAT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; BLOOD DONOR; BLOOD TRANSFUSION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN T CELL LEUKEMIA VIRUS 1; HUMAN T CELL LEUKEMIA VIRUS 2; HUMAN T CELL LEUKEMIA VIRUS INFECTION; MALE; MULTIVARIATE ANALYSIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROVIRUS; REAL TIME POLYMERASE CHAIN REACTION; SEX DIFFERENCE; VIRUS LOAD;

EID: 3242776966     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/422398     Document Type: Article

References (42)

1. Cann AJ, Chen ISY. Human T-cell leukemia virus types I and II. In: Fields B, ed. Virology. 2nd ed. New York: Raven Press, 1990:1501-27.
2. Slattery JP, Franchini G, Gessain A. Genomic evolution, patterns of global dissemination, and interspecies transmission of human and simian T-cell leukemia/lymphotropic viruses. Genome Res 1999; 9:525-40.
3. Manns A, Hisada M, La Grenade L. Human T-lymphotropic virus type I infection. Lancet 1999; 353:1951-8.
4. Hall WW, Ishak R, Zhu SW, et al. Human T lymphotropic virus type II (HTLV-II): epidemiology, molecular properties, and clinical features of infection. J Acquir Immune Defic Syndr Hum Retrovirol 1996; 13(Suppl 1):S204-14.
5. Murphy EL. The clinical epidemiology of human T-lymphotropic virus type II (HTLV- II). J Acquir Immune Defic Syndr Hum Retrovirol 1996; 13(Suppl 1):S215-9.
6. Wattel E, Vartanian JP, Pannetier C, Wain-Hobson S. Clonal expansion of human T-cell leukemia virus type I-infected cells in asymptomatic and symptomatic carriers without malignancy. J Virol 1995; 69:2863-8.
7. Igakura T, Stinchcombe JC, Goon PK, et al. Spread of HTLV-I between lymphocytes by virus-induced polarization of the cytoskeleton. Science 2003; 299:1713-6.
8. Mahieux R, Pise-Masison CA, Nicot C, Green P, Hall WW, Brady JN. Inactivation of p53 by HTLV type 1 and HTLV type 2 Tax transactivators. AIDS Res Hum Retroviruses 2000; 16:1677-81.
9. Nagai M, Usuku K, Matsumoto W, et al. Analysis of HTLV-I proviral load in 202 HAM/TSP patients and 243 asymptomatic HTLV-I carriers: high proviral load strongly predisposes to HAM/TSP. J Neurovirol 1998; 4:586-93.
10. + T cells, and disease severity in HTLV-I-associated myelopathy (HAM/TSP). Blood 2002; 99:88-94.
11. Osame M. Overview, epidemiology and clinical features of HTLV-I-associated myelopathy (HAM/TSP). Clin Neurol 1988; 28:1375-8.
12. Levin MC, Lee SM, Kalume F, et al. Autoimmunity due to molecular mimicry as a cause of neurological disease. Nat Med 2002; 8:509-13.
13. Jacobson S. Immunopathogenesis of human T cell lymphotropic virus type I-associated neurologic disease. J Infect Dis 2002; 186(Suppl 2): S187-92.
14. Manns A, Miley WJ, Wilks RJ, et al. Quantitative proviral DNA and antibody levels in the natural history of HTLV-I infection. J Infect Dis 1999; 180:1487-93.
15. Tachibana N, Okayama A, Ishihara S, et al. High HTLV-I proviral DNA level associated with abnormal lymphocytes in peripheral blood from asymptomatic carriers. Int J Cancer 1992; 51:593-5.
16. Cimarelli A, Duclos CA, Gessain A, et al. Quantification of HTLV-II proviral copies by competitive polymerase chain reaction in peripheral blood mononuclear cells of Italian injecting drug users, central Africans, and Amerindians. J Acquir Immune Defic Syndr Hum Retrovirol 1995; 10:198-204.
17. Woods TC, Graber JM, Hershow RC, Khabbaz RF, Kaplan JE, Heneine W. Investigation of proviral load in individuals infected with human T-lymphotropic virus type II. AIDS Res Hum Retroviruses 1995; 11:1235-9.
18. Beilke MA, Japa S, Vinson DG. HTLV-I and HTLV-II virus expression increase with HIV-1 coinfection. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 17:391-7.
19. Zehender G, Meroni L, Varchetta S, et al. Human T-lymphotropic virus type 2 (HTLV-2) provirus in circulating cells of the monocyte/macrophage lineage in patients dually infected with human immunodeficiency virus type 1 and HTLV-2 and having predominantly sensory polyneuropathy. J Virol 1998; 72:7664-8.
20. Murphy EL, Grant RM, Kropp J, Oliveira A, Lee T-H, Busch MP. Increased HTLV-II proviral load following highly active retroviral therapy in HIV-coinfected patients. J Acquir Immune Defic Syndr 2003; 33:655-6.
21. Machuca A, Soriano V. In vivo fluctuation of HTLV-I and HTLV-II proviral load in patients receiving antiretroviral drugs. J Acquir Immune Defic Syndr 2000; 24:189-93.
22. Murphy EL, Watanabe K, Nass CC, Ownby H, Williams A, Nemo G. Evidence among blood donors for a 30-year-old epidemic of human T lymphotropic virus type II infection in the United States. J Infect Dis 1999; 180:1777-83.
23. Murphy EL, Glynn SA, Fridey J, et al. Increased incidence of infectious diseases during prospective follow-up of human T-lymphotropic virus type II- and I-infected blood donors. Retrovirus Epidemiology Donor Study. Arch Intern Med 1999; 159:1485-91.
24. Murphy EL, Wang B, Sacher RA, et al. Respiratory and urinary tract infections, arthritis and asthma associated with HTLV-I and HTLV-II infection. Emerg Infect Dis 2004; 10:109-16.
25. Busch MP, Laycock M, Kleinman SH, et al. Accuracy of supplementary serologic testing for human T-lymphotropic virus types I and II in US blood donors. Retrovirus Epidemiology Donor Study. Blood 1994; 83:1143-8.
26. Liu H, Leung P, Glynn S, Murphy EL. Human T-lymphotropic virus type II RFLP subtypes aO and b4/b5 are associated with different demographic and geographic characteristics in the United States. Virology 2001; 279:90-6.
27. Kaplan JE, Khabbaz RF, Murphy EL, et al. Male-to-female transmission of human T-cell lymphotropic virus types I and II: association with viral load. The Retrovirus Epidemiology Donor Study Group. J Acquir Immune Defic Syndr Hum Retrovirol 1996; 12:193-201.
28. Albrecht B, Collins ND, Newbound GC, Ratner L, Lairmore MD. Quantification of human T-cell lymphotropic virus type 1 proviral load by quantitative competitive polymerase chain reaction. J Virol Methods 1998; 75:123-40.
29. Cimarelli A, Duclos CA, Gessain A, Casoli C, Bertazzoni U. Clonal expansion of human T-cell leukemia virus type II in patients with high proviral load. Virology 1996; 223:362-4.
30. Endo K, Hirata A, Iwai K, et al. Human T-cell leukemia virus type 2 (HTLV-2) Tax protein transforms a rat fibroblast cell line but less efficiently than HTLV-1 Tax. J Virol 2002; 76:2648-53.
31. Mahieux R, Pise-Masison CA, Lambert PF, et al. Differences in the ability of human T-cell lymphotropic virus type 1 (HTLV-1) and HTLV-2 Tax to inhibit p53 function. J Virol 2000; 74:6866-74.
32. Lewis MJ, Sheehy N, Salemi M, VanDamme AM, Hall WW. Comparison of CREB- and NF-κB-mediated transactivation by human T lymphotropic virus type II (HTLV-II) and type I (HTLV-I) Tax proteins. Virology 2002; 295:182-9.
33. Ross TM, Minella AC, Fang ZY, Pettiford SM, Green PL. Mutational analysis of human T-cell leukemia virus type 2 Tax. J Virol 1997; 71:8912-7.
34. Schreiber GB, Murphy EL, Horton JA, et al. Risk factors for human T-cell lymphotropic virus types I and II (HTLV-I and -II) in blood donors: the Retrovirus Epidemiology Donor Study. NHLBI Retrovirus Epidemiology Donor Study. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 14:263-71.
35. Taylor GP, Tosswill JH, Matutes E, et al. Prospective study of HTLV-I infection in an initially asymptomatic cohort. J Acquir Immune Defic Syndr 1999; 22:92-100.
36. Etoh K, Yamaguchi K, Tokudome S, et al. Rapid quantification of HTLV-I provirus load: detection of monoclonal proliferation of HTLV-I-infected cells among blood donors. Int J Cancer 1999; 81:859-64.
37. Orland JR, Engstrom J, Fridey J, et al. Prevalence and clinical features of HTLV neurologic disease in the HTLV outcomes study. Neurology 2003; 61:1588-94.
38. Kramer A, Maloney EM, Morgan OS, et al. Risk factors and cofactors for human T-cell lymphotropic virus type I (HTLV-I)-associated myelopathy/tropical spastic paraparesis (HAM/TSP) in Jamaica. Am J Epidemiol 1995; 142:1212-20.
39. Wilks R, Hanchard B, Morgan O, et al. Patterns of HTLV-I infection among family members of patients with adult T-cell leukemia/lymphoma and HTLV-I associated myelopathy/tropical spastic paraparesis. Int J Cancer 1996; 65:272-3.
40. Iga M, Okayama A, Stuver S, et al. Genetic evidence of transmission of human T cell lymphotropic virus type 1 between spouses. J Infect Dis 2002; 185:691-5.
41. Moules V, Gabet AS, Nass CC, et al. Endemic versus epidemic viral spreads display distinct patterns of intraindividual HTLV-2 replication (abstract O60). AIDS Res Hum Retroviruses 2003; 19(Suppl):S24.
42. Jeffery KJ, Usuku K, Hall SE, et al. HLA alleles determine human T-lymphotropic virus-I (HTLV-I) proviral load and the risk of HTLV-I-associated myelopathy. Proc Natl Acad Sci USA 1999; 96:3848-53.